naltrexone has been researched along with Dyslipidemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Apovian, CM; Aronne, L; Burns, C; Dunayevich, E; Kim, D; Rubino, D; Still, C; Wyatt, H | 1 |
| Dybala, C; Foreyt, JP; Halseth, AE; Herrmann, K; Hong, K; Lam, H | 1 |
2 trial(s) available for naltrexone and Dyslipidemia
| Article | Year |
|---|---|
A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
Topics: Adult; Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Delayed-Action Preparations; Dopamine Uptake Inhibitors; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Feeding Behavior; Female; Humans; Hypertension; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nausea; Obesity; Overweight; Quality of Life; Risk Factors; Weight Loss | 2013 |
Naltrexone/Bupropion extended release-induced weight loss is independent of nausea in subjects without diabetes.
Topics: Adult; Anti-Obesity Agents; Body Mass Index; Bupropion; Combined Modality Therapy; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Female; Humans; Hypertension; Incidence; Lost to Follow-Up; Male; Naltrexone; Nausea; Obesity; Overweight; Patient Dropouts; Severity of Illness Index; United States; Weight Loss | 2016 |